How Long Till Wegovy Works: A Realistic Week-by-Week Picture

Step 1: The first four weeks, appetite shifts before weight does

The opening pen contains 0.25 mg semaglutide, a dose chosen purely to help your body adjust rather than to drive significant weight loss. Many people find this phase underwhelming on the scales. That is expected. What tends to happen underneath is more interesting: GLP-1 receptor agonism slows gastric emptying and dials down hunger signals, so food becomes less preoccupying within days for most people. You might notice you feel full from smaller portions, or that the mid-afternoon craving you've had for years simply doesn't show up.

Some people also notice mild nausea at this stage. The NHS medicines page for semaglutide describes GI effects as common but typically short-lived, settling as the body acclimatises. Keeping the pen in a consistent spot (many people use the fridge door) builds the habit of the weekly injection without it becoming a chore.

If you are wondering how long until Wegovy works, the honest answer is that appetite changes often arrive before the scales move, so this first month matters more than the number it produces. The point of this month is laying the foundation, not racing.

Step 2: Weeks four to sixteen (dose increases and the scales start moving

From week five the prescriber moves you to 0.5 mg, then to 1.0 mg at week nine, and to 1.7 mg around week thirteen) each step roughly four weeks apart. This staircase structure exists because tolerance and effect both build with the dose; the higher you go, the more pronounced the appetite suppression. Weight loss tends to accelerate meaningfully through this phase. A realistic range for the first three to four months is five to eight per cent of starting body weight, though individual results vary considerably.

People who want a granular picture of the early weeks often read alongside our page on how fast Wegovy works, which breaks down what the trial data says about early responders. Nausea and loose stools are most common during or just after dose steps, then usually ease. Staying well hydrated and eating smaller, lower-fat meals at this stage helps.

One thing the clinical trial data makes clear: early weight loss is not the ceiling. Participants in the STEP 1 trial, published in the New England Journal of Medicine, continued losing weight for the full 68 weeks of the study, the curve does not flatten at month three.

Step 3: Month four to eighteen, the 2.4 mg maintenance phase and peak results

Most people reach the 2.4 mg maintenance dose around week seventeen. From here, the medicine is at full strength and this is where the bulk of total weight loss tends to occur. The STEP 1 trial recorded an average reduction of around 15% of body weight by 68 weeks at 2.4 mg. That figure comes from a broad population, so some participants lost considerably more and some less, it is an average, not a target.

Progress in the maintenance phase often feels slower on a week-by-week basis than it did during titration. Plateaus of two to four weeks are common and reflect normal metabolic adaptation. Continuing treatment, keeping activity up and eating enough protein all matter here. For context on the maximum outcomes seen in trials, the page on maximum weight loss on Wegovy sets out what the evidence shows at the higher end.

Thinking ahead to what happens if you stop is also worth raising with your prescriber early. The evidence on maintaining weight after Wegovy is a conversation every patient should have before reaching month twelve, not because it changes what to do now, but because knowing the plan reduces anxiety about dependence. Wegovy is a prescription medicine; decisions about duration sit with the prescriber reviewing your progress.

When results are slower than expected, and when to say something

If you have not lost at least 5% of your starting body weight after six months on the full maintenance dose, NICE guidance for semaglutide suggests reviewing whether the treatment is working for you. That review is a clinical one, not a self-assessment. Your prescriber looks at what dose you reached, whether side effects limited titration, adherence, and other individual factors before drawing any conclusion.

Slower progress can reflect dose tolerance, a need to adjust the lifestyle components running alongside treatment, or occasionally a reason to reconsider the medicine altogether. None of these are failures. The question our clinical team hears most often at this stage is whether a different medicine might suit better, the broader semaglutide timeline page sets this in context, and a prescriber conversation is the right place to weigh the options.

If you are considering starting treatment or want to understand whether Wegovy fits your situation, you can read more about the service on the Wegovy overview page or go straight to check your eligibility with our prescribers, the consultation is free, reviewed the same day by a GPhC-registered clinician, and carries no obligation.